All Sushant Sahastrabuddhe articles
-
NewsIndia could bear biggest impact from chikungunya, new maps suggest
Based on existing evidence of chikungunya transmission, an infectious disease model predicts 14.4 million people could be at risk of infections globally each year, with 5.1 million people at risk in India.
-
NewsSK bioscience’s typhoid conjugate vaccine achieves WHO prequalification
SK bioscience and the International Vaccine Institute (IVI) announced that the typhoid conjugate vaccine developed by SK bioscience with technology transfer from IVI has achieved the World Health Organization prequalification (PQ).
-
NewsNew typhoid conjugate vaccine Bio-TCV® approved in Indonesia
Bio Farma’s Bio-TCV® typhoid conjugate vaccine (TCV) has been licensed in Indonesia following marketing approval from Badan Pengawas Obat dan Makanan (BPOM), the national regulatory authority.